Cell Biology Laboratory and Malaria Parasite Bank, ICMR-National Institute of Malaria Research, Sector 8, Dwarka, New Delhi, 110077, India.
Malar J. 2020 Jan 28;19(1):46. doi: 10.1186/s12936-019-3090-6.
In 2017, nearly 80% of malaria morbidity and mortality occurred in sub-Saharan African (SSA) countries and India. Rapid diagnostic tests (RDTs), especially those targeting histidine-rich protein 2 (PfHRP2) of Plasmodium falciparum, have become an important diagnostic tool in these malaria-endemic areas. However, the chances of RDT-oriented successful treatment are increasingly jeopardized by the appearance of mutants with deletions in pfhrp2 and pfhrp3 genes. This systematic review and meta-analysis determines the prevalence of field P. falciparum isolates with deletion in pfhrp2 and/or pfhrp3 genes and their proportion among false-negative results in the PfHRP2-based RDTs in SSA and India.
Eight electronic databases were used for searching potentially relevant publications for the systematic review analysis, wherein the main methodological aspects of included studies were analysed and some missing links in the included studies were identified.
A total of 19 studies were included, 16 from SSA and 3 from India. The pooled prevalence of pfhrp2 deletions was 8 and 5% while 16 and 4% for pfhrp3 gene deletions in Africa and India, respectively. The pooled proportion of pfhrp2 gene deletions found among false negative PfHRP2-based RDTs results was about 27.0 and 69.0% in Africa and India, respectively.
This review study indicates a relatively high proportion of both pfhrp2/3 genes deletions in P. falciparum isolates and among false-negative malaria cases using PfHRP2-based RDT results in SSA and India. Recently the deletions in pfhrp2/3 genes have also been reported from two African countries (Nigeria and Sudan). This review emphasizes the importance of more extensive studies and standardization of studies addressing the pfhrp2/3 gene deletions in malarious areas.
2017 年,近 80%的疟疾发病率和死亡率发生在撒哈拉以南非洲(SSA)国家和印度。快速诊断检测(RDT),特别是针对恶性疟原虫(Plasmodium falciparum)组氨酸丰富蛋白 2(PfHRP2)的 RDT,已成为这些疟疾流行地区的重要诊断工具。然而,RDT 导向的成功治疗机会越来越受到 pfhrp2 和 pfhrp3 基因缺失突变体的出现的威胁。本系统评价和荟萃分析确定了 SSA 和印度 PfHRP2 基于 RDT 假阴性结果中 pfhrp2 和/或 pfhrp3 基因缺失的现场恶性疟原虫分离株的流行率及其比例。
使用 8 个电子数据库搜索系统评价分析中潜在相关的出版物,对纳入研究的主要方法学方面进行分析,并确定纳入研究中的一些缺失环节。
共纳入 19 项研究,其中 16 项来自 SSA,3 项来自印度。pfhrp2 缺失的总流行率分别为非洲的 8%和 5%,印度的 16%和 4%。pfhrp2 基因缺失在 PfHRP2 基于 RDT 假阴性结果中的发现比例分别为非洲的 27.0%和印度的 69.0%。
本综述研究表明,在 SSA 和印度,PfHRP2 基于 RDT 假阴性疟疾病例中,恶性疟原虫分离株的 pfhrp2/3 基因缺失比例相对较高。最近,在两个非洲国家(尼日利亚和苏丹)也报告了 pfhrp2/3 基因缺失。本综述强调了在疟疾流行地区进行更广泛的研究和标准化研究以解决 pfhrp2/3 基因缺失问题的重要性。